Patent intelligence · US
US 8450337
Methods of treating skin disorders with caffeic acid analogs
Methods of treating skin disorders with caffeic acid analogs
Patent details — US 8450337
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2013
- Expiration
- May 23, 2033
- Applicant
- Moleculin, LLC
- Claims
- 6
- CPC classes
- A61K, A61K31/203, A61K31/44, A61K31/59
Quick answer
US 8450337 (Methods of treating skin disorders with caffeic acid analogs) is held by Moleculin, LLC. Status: granted. Granted May 28, 2013. Expires May 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Moleculin, LLC
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/203, A61K31/44, A61K31/59, A61K45/06, A61P
Frequently asked questions
What is US patent 8450337?
US 8450337 (Methods of treating skin disorders with caffeic acid analogs) is held by Moleculin, LLC. Status: granted. Granted May 28, 2013. Expires May 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8450337?
Moleculin, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 8450337 expire?
Our index shows an expiration date of May 23, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.